Skip to content

Stock·NASDAQ·Healthcare

Amgen Inc. (AMGN)

$435.64 -3.18 (-0.72%)
At close: Nov 20, 4:00 PM EST
Buy
71 / 100
CleaRank Financial AI scorei
Market cap
$235.64B
P/E
25.25
Dividend yield
2.31%
Street target
$440.00median of 34 analysts
52-week range
$312.39 $483.99

What moved Amgen Inc. (AMGN)

Market figures as of November 20, 2026.

Was it the market or the company?

On November 20, 2026, AMGN fell 0.72%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.

The move was in line with the market. AMGN's one-year beta to SPY is 0.51, so SPY's -3.64% would on average have meant -1.85% for AMGN, close to what it did (1.1 percentage points less).

Over the last 20 sessions AMGN is down 0.82% against -9.23% for SPY, 8.4 percentage points ahead of it.

The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)

Moves to November 20, 2026, side by side
That day 5 sessions 20 sessions
AMGN -0.72% -6.45% -0.82%
S&P 500 (SPY) -3.64% -8.56% -9.23%
Nasdaq 100 (QQQ) -5.67% -10.51% -13.62%
Health care sector (XLV) -0.12% -6.15% -1.14%

Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.

01

AMGN stock today, November 22, 2026: price, news and analyst targets

As of November 20, 2026, Amgen Inc. (AMGN) trades at $435.64. Wall Street's median 12-month price target is $440.00 across 34 analysts, 1.0% above the price. CleaRank rates it Buy with a score of 71/100.

Amgen's stock has pulled back after a volatile week, falling 6.45% over the last week and 3.07% on November 18, 2026, when it closed at $443.89. It still trades 33.10% higher year to date and 13.62% above its 200-day average, and it sits in the upper part of its 52-week range. Analysts are split: the median 12-month target is $440.00, almost exactly where the stock trades, and the consensus rating is Hold. The company reported third-quarter adjusted EPS of $6.45 on November 3, 2026, beating the $5.78 estimate, and the shares rose 3.73% the next session.

Why the stock fell this week

Shares fell 6.45% over the past week, including a 3.07% drop on November 18, 2026, when the stock closed at $443.89. The decline is best read as a short-term pullback after a strong year rather than a change in the earnings picture. Over one month the stock is down only 0.62%, and over six months it is up 28.39%.

Earnings have beaten estimates

Amgen has beaten the EPS estimate in each of its last eight reports, including the November 3, 2026 report, where adjusted EPS of $6.45 came in 11.59% above the $5.78 estimate. The stock rose 3.73% in the first session after that report. Not every beat was rewarded: three of the eight beats were followed by a lower share price in the first session, so a beat alone has not reliably lifted the stock.

Valuation and balance sheet

The trailing P/E of 25.25 is at a discount to peers, sitting 20.8% below the sector median of 31.9. The price-to-sales ratio of 6.06 is well above the sector median of 3.4, and the stock trades with a return on equity of 78.35% against a sector median of 7.3%. Debt is high, with a debt-to-equity ratio of 3.76, and the trailing dividend yield is 2.31% on an annual dividend of $10.08. The stock beats the market's risk profile with a beta of 0.42 against the S&P 500.

Analysts are divided

Of 34 analysts, 11 rate the stock buy or strong buy, 18 hold it and 5 sell it. Three months ago 14 of 34 rated it buy. In the most recent actions, Argus Research kept its Buy rating on November 12, 2026, and UBS kept its Buy rating on November 4, 2026, while Freedom Broker downgraded the stock to Hold from Buy on November 6, 2026. Insiders sold $30.1M of stock over the last 18 months across 11 sales and made no open-market purchases; those sales are often planned in advance or made to cover taxes on vesting shares.

CleaRank score 71/100 (Buy). 15 of 19 checks pass: trend 4 of 4, momentum 2 of 3, valuation and quality 4 of 5, analysts 1 of 3, track record 4 of 4.

About Amgen

Amgen Inc. , a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc.

02

AMGN stock news

  • Earnings beat and rise

    ·Earnings report

    Adjusted EPS of $6.45 beat the $5.78 estimate by 11.59%, and the shares rose 3.73% in the next session. This is the clearest recent evidence that results are running ahead of expectations.

  • Buy rating kept by Argus

    ·Argus Research

    Argus Research kept its Buy rating on November 12, 2026, a supportive view as the stock works through its recent pullback.

  • Downgrade to Hold

    ·Freedom Broker

    Freedom Broker cut its rating to Hold from Buy on November 6, 2026, reducing the number of buy-side voices at a time when the stock is near the median target.

  • Buy rating held by UBS

    ·UBS

    UBS kept its Buy rating on November 4, 2026, one of several reiterations that show analysts remain divided rather than moving toward a clear consensus.

  • Hold ratings maintained

    ·Canaccord Genuity

    Leerink Partners, Guggenheim and Canaccord Genuity all kept their non-buy ratings in early November, so the majority view is still neutral.

03

AMGN price target 2026

The base case is that Amgen keeps growing earnings in line with its estimates while the stock trades near the analysts' median target. Analysts expect EPS to rise 7.8% this fiscal year to $23.53 and 6.4% next year to $25.04, and revenue to grow 7.5% to $39.5B this year. A stock priced close to the median target leaves limited room for a re-rating unless those estimates move up. The bull case needs continued beats, like the 11.59% beat in November, and a return toward the 52-week high of $483.99. The bear case is a loss of the 50-day average at $430.45, which would bring the 200-day average at $383.40 into view, or a further downgrade following the November 6 cut to Hold by Freedom Broker. Simulations from past volatility are not forecasts, and the typical daily move of 1.73% means large swings remain normal.

Analyst targets and ratings

12-month price targets

Low $230.00 Median $440.00 (+1.0%) High $536.00

Ratings

Buy 11 Hold 18 Sell 5 3 months ago: 14 of 34 buy

Recent rating actions

Recent analyst rating actions on AMGN
Date Firm Action Rating
Nov 12, 2026 Argus Research Maintains Buy
Nov 6, 2026 Freedom Broker Downgrade Hold
Nov 5, 2026 Leerink Partners Maintains Market Perform
Nov 5, 2026 Guggenheim Maintains Neutral
Nov 4, 2026 Canaccord Genuity Maintains Hold
Nov 4, 2026 UBS Maintains Buy
04

AMGN support and resistance levels

Support sits first at the 50-day simple moving average of $430.45, which the price is just above, followed by the 200-day simple moving average of $383.40. The 52-week low of $312.39 is the deepest reference below the price. Resistance comes first from the 20-day exponential moving average at $451.57, which the price is below, then the 52-week high of $483.99. A close back above the 20-day average would be the first sign the recent drop is being reversed, while the 50-day average marks where buyers have defended the stock recently.

AMGN support and resistance levels
Level What it is Price From the price
Resistance 2 52-week high $483.99 +11.1%
Resistance 1 20-day exponential average $451.57 +3.7%
Price November 20, 2026 $435.64
Support 1 50-day moving average $430.45 -1.2%
Support 2 200-day moving average $383.40 -12.0%
Support 3 52-week low $312.39 -28.3%

Technical indicators

Technical rating Bullish 3 of 4 signals bullish
  • RSI Neutral
  • SMA cross Bullish
  • Price vs SMA Bullish
  • MACD Bullish
Momentum Neutral
41.014-day RSI
Oversold <30 Neutral Overbought >70
MACD (12, 26) 3.51 Bullish
Trend Golden cross
+1.2%price against the 50-day average
200-day $383.40 50-day $430.45 Price $435.64
Price against the 200-day +13.6% Bullish

AMGN technical analysis in depth

Volatility, momentum, trend strength and the price levels that matter for AMGN, calculated by CleaRank from daily bars to November 20, 2026.

Volatility

On the 20-day Bollinger Bands (2 standard deviations) the bands run from $436.82 to $479.87 around a middle of $458.35, and AMGN's close of $435.64 sits below the lower band, a stretched reading.

Band width is 9.4% of the price, in the middle of its range over the last 120 sessions.

The 14-day average true range is $11.58, or 2.7% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 4.0% from the close.

Momentum and volume

The 14-day stochastic reads 2 (signal line 5): the close is near the bottom of its two-week range, an oversold zone.

The MACD line (12, 26) is 3.51 against a signal line (9) of 8.53, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 6 sessions ago.

Volume in the latest session was 1.9 times its 20-day average, heavy enough to give the move more weight.

Trend strength

The 14-day ADX is 29: a trending market, with sellers in control (+DI 25, -DI 25).

On the weekly chart the 10-week average ($431.77) is above the 40-week average ($383.85), a rising longer-term trend, and the weekly RSI is 57.

Key levels

The nearest resistance from the price history is $446.63 (+2.5%): the price turned here 3 times, most recently on November 6, 2026.

The nearest support is $426.59 (-2.1%): a swing low set on September 30, 2026.

The largest swing of the last 120 sessions ran up from $325.98 (June 3, 2026) to $483.99 (November 5, 2026); the nearest Fibonacci retracement to the price is the 23.6% level at $446.70.

Classic pivot points for the next session, from November 20, 2026: pivot $438.55, resistance $442.58 and $449.53, support $431.60 and $427.57.

AMGN key price levels
Level Price From the price What it is
Resistance (swing high) $483.99 +11.1% a swing high set on November 5, 2026
Upper Bollinger Band $479.87 +10.2% 20-day average + 2 standard deviations
Pivot R2 (classic) $449.53 +3.2% next-session level
Fibonacci 23.6% $446.70 +2.5% retracement of the rise from $325.98 to $483.99
Resistance (swing high) $446.63 +2.5% the price turned here 3 times, most recently on November 6, 2026
Pivot R1 (Fibonacci) $442.74 +1.6% 38.2% of the last range above the pivot
Pivot R1 (classic) $442.58 +1.6% next-session level
Pivot point $438.55 +0.7% average of the last high, low and close
Lower Bollinger Band $436.82 +0.3% 20-day average - 2 standard deviations
Price $435.64 close, November 20, 2026
Pivot S1 (Fibonacci) $434.35 -0.3% 38.2% of the last range below the pivot
Pivot S1 (classic) $431.60 -0.9% next-session level
Pivot S2 (classic) $427.57 -1.9% next-session level
Support (swing low) $426.59 -2.1% a swing low set on September 30, 2026
Fibonacci 38.2% $423.63 -2.8% retracement of the rise from $325.98 to $483.99
Fibonacci 50.0% $404.99 -7.0% retracement of the rise from $325.98 to $483.99
Support (swing low) $395.10 -9.3% the price turned here 3 times, most recently on October 6, 2026
Fibonacci 61.8% $386.34 -11.3% retracement of the rise from $325.98 to $483.99
Support (swing low) $378.74 -13.1% the price turned here 4 times, most recently on September 16, 2026
Fibonacci 78.6% $359.79 -17.4% retracement of the rise from $325.98 to $483.99

Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.

05

AMGN stock price and trading

AMGN share price

Start $336.07 Nov 20, 2025
Latest close $435.64 Nov 20, 2026
High $478.48 Nov 4, 2026
Low $313.85 Dec 9, 2025
06

AMGN fundamentals and valuation

Key statistics

Market Cap
235.64B
P/E Ratio
25.25
EPS (TTM)
$17.25
Dividend Yield
2.31%
52 Week High
483.99
52 Week Low
312.39

AMGN against the Healthcare sector

P/E ratio 21% below the median
AMGN
25.3x
Sector median
31.9x
P/S ratio 78% above the median
AMGN
6.1x
Sector median
3.4x
Revenue growth, year on year 1.4 points above the median
AMGN
9.5%
Sector median
8.1%
Return on equity 71.1 points above the median
AMGN
78.4%
Sector median
7.3%

Price to earnings vs sector: AMGN trades at a notable discount to sector peers (-21% against the sector median P/E). Investors are paying less for each dollar of earnings than for the typical stock in the sector.

Return vs XLV: Since Jun 11, 2025, AMGN has gained 49.3% against a gain of 30.6% for XLV.

Performance against XLV

AMGN XLV

Revenue and earnings

Revenue, 12 months
$38.9B
Net income, 12 months
$9.4B
Net margin
24.1%
Revenue growth
+9.5%
Q2 '26, year on year
FY202123% marginFY202225% marginFY202324% marginFY202412% marginFY202521% margin
Revenue Net income

Revenue growth: Revenue grew 10.0% in FY2025 to $36.8B, from $33.4B a year earlier.

Profit margin: The net margin was 21.0% in FY2025, up from 12.2% the year before.

Profitable: AMGN earned $7.7B in FY2025.

Earnings reality check

Beat the estimate
8 of 8
last 8 reports
Fell after a beat
3 of 8
first session after the report
Average surprise
+11.2%
actual EPS against the estimate
Avg. first-session move
+2.5%
the stock, after the report
EPS surprise
First-session move
Feb '25May '25Aug '25Nov '25Feb '26Apr '26Aug '26Nov '26

Earnings record: AMGN beat the analyst estimate in 8 of the last 8 quarters.

Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.

AMGN earnings surprises and the stock's reaction
Report Estimate Actual Surprise First session 5 sessions
Nov 3, 2026after close $5.78 $6.45 +11.59% +3.73% +0.86%
Aug 4, 2026after close $5.62 $6.29 +11.92% +4.57% +6.23%
Apr 30, 2026after close $4.77 $5.15 +7.97% -4.75% -4.96%
Feb 3, 2026after close $4.73 $5.29 +11.84% +8.15% +7.70%
Nov 4, 2025after close $5.01 $5.64 +12.57% +7.81% +14.07%
Aug 5, 2025after close $5.28 $6.02 +14.02% -5.14% -5.03%
May 1, 2025after close $4.26 $4.90 +15.02% -0.90% -4.13%
Feb 4, 2025after close $5.08 $5.31 +4.53% +6.50% +2.64%
07

AMGN price history and drawdowns

Risk profile

Beta
0.42
against the S&P 500; 1 moves with the market
Daily volatility
1.73%
30-day standard deviation
52-week range
$435.64
$312.39 72% of the way up $483.99

Worst falls and recoveries

Worst fall, last 10 years
-23.0%
November 2022 to May 2023
Recovery
5 months
back at the old peak by October 2023
From the 10-year high
-8.5%
peak with dividends reinvested, November 2026
1-year holds that gained
78%
of every 1-year window

Growth of $10,000

AMGN today
$41,120
from $10,000 in December 2016, dividends reinvested
S&P 500 today
$36,764
the same $10,000 in SPY, dividends reinvested
Ahead of the index by
$4,356
1.1x the index result
Total change
+311%
4.1x the starting amount
AMGN S&P 500 (SPY)

Against the market: AMGN beat the S&P 500 over this period: $41,120 against $36,764.

A $10,000 investment in AMGN in December 2016 would be worth about $41,120 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).

08

AMGN stock price prediction 2030

AMGN Stock Price Prediction 2030: Simulated Scenarios

Price today
$436
Base case, 2030
$599
1.4x over 4 years
Range, 2030
$315 to $1,140
10th to 90th percentile

CleaRank's simulation projects a price near $599 for AMGN by 2030 in the base case, from $436 today (1.4x over 4 years). The 10th-percentile path ends near $315. These are outcomes of a Monte Carlo simulation run on AMGN's historical return distribution, not price targets, and they assume no dividends are reinvested.

AMGN simulated price paths by year
Year 10th percentile Base case 90th percentile range base today
2027 $342 $472 $651
2028 $324 $511 $805
2029 $317 $553 $966
2030 $315 $599 $1,140
09

AMGN insider trading

AMGN insider trading

Bought
None
no open-market buys
Sold
$30.1M
11 open-market sales
Insiders filing
23
over the last 18 months
Average trade
$2.7M
buys and sales together

Month by month

Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26Nov '26

Net insider selling: No insider bought AMGN shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.

Insider transactions in AMGN
Date Insider Type Shares Value
Nov 6, 2026
Michael V Drake
Director
Grant 114 -
Nov 6, 2026
David W Gibbs
Director
Grant 278 -
Nov 6, 2026
Charles M Holley Jr
Director
Grant 184 -
Nov 6, 2026
Omar Syed Ishrak
Director
Grant 152 -
Aug 13, 2026
Rachna Khosla
Officer
Sell 3.3K $1.3M
Aug 13, 2026
Rachna Khosla
Officer
Option 1.3K $203.6K
Aug 7, 2026
Matthew C. Busch
Officer
Grant 730 -
Aug 7, 2026
Michael V Drake
Director
Grant 63 -
Aug 7, 2026
Charles M Holley Jr
Director
Grant 103 -
Aug 7, 2026
Omar Syed Ishrak
Director
Grant 85 -
10

AMGN stock forecast: questions people ask

AMGN Forecast: Frequently Asked Questions

What is the AMGN stock forecast?
The analysts' median 12-month price target is $440.00, 1.0% above the price, with the lowest target at $230.00 and the highest at $536.00 across 34 analysts. The nearest level below the price is the 50-day simple moving average at $430.45, and the nearest level above is the 20-day exponential moving average at $451.57.
What is the AMGN price target?
The median 12-month analyst target is $440.00, with the lowest at $230.00 and the highest at $536.00. The consensus rating is Hold, and the price of $435.64 is 1.0% below the median target.
Is AMGN a buy or sell today?
Analysts rate the stock Hold on consensus, with 11 of 34 rating it buy or strong buy, 18 hold and 5 sell or strong sell. CleaRank rates the stock Buy with a score of 71 out of 100. The trend is up, with the price 1.21% above its 50-day average and 13.62% above its 200-day average.
How has Amgen's earnings record held up?
Amgen beat the EPS estimate in all 8 of its last reports. The November 3, 2026 report showed adjusted EPS of $6.45 against a $5.78 estimate, an 11.59% beat.
Why is AMGN trading below its 52-week high?
The price is 9.99% below the 52-week high of $483.99. The stock fell 3.07% on November 18, 2026, closing at $443.89.
How does AMGN's valuation compare with its sector?
The trailing P/E of 25.25 is 20.8% below the sector median of 31.9, which is at a discount to peers. The price-to-sales ratio of 6.06 is above the sector median of 3.4.

How these figures are computed, and where the data comes from: CleaRank methodology.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The stock analysis and AI-generated signals presented for AMGN are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. Simulated scenarios and historical performance figures shown are hypothetical and hindsight-based. They do not represent actual trades made by CleaRank or its affiliates. Stock prices can be volatile and are subject to market, economic, and company-specific risks. Market data is provided "as-is" and may be delayed by up to a minute. We do not guarantee the accuracy, completeness, or timeliness of any data. You should never invest money you cannot afford to lose. Past performance does not guarantee future results. Consult a qualified financial advisor before making any investment decisions. Analysis generated on November 22, 2026.